Studies whose primary subject is both MDMA and Depression, with an evidence synthesis read across the most-cited and most recent of them.
Synthesized from 25 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for MDMA, ecstasy, molly, methylenedioxymethamphetamine, Depression, major depressive disorder, then ranked by relevance.
Direct evidence on MDMA for depression is thin: the strongest data concern PTSD, where MDMA-assisted therapy reduces symptoms and also appears to improve comorbid depression in meta-analysis. One large survey found recreational ecstasy use associated with lower odds of past-year major depressive episode, but this is observational and confounded. Overall, MDMA-assisted therapy for depression itself remains largely unproven, with small samples, blinding problems, and no long-term durability data.
Direction is which way each study's own result points, not our rating of the study.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| 3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial. 2018 | RCT | 28 | Supports | Active MDMA doses (100 and 125 mg) with psychotherapy produced larger PTSD symptom reductions than a 40 mg dose, though significance was reached only in the per-protocol set, and 76% no longer met PTSD criteria at 12 months. |
| Registered clinical studies investigating psychedelic drugs for psychiatric disorders. 2021 | review | 70 | Unclear | Most registered MDMA and psilocybin trials targeted PTSD and major depressive disorder, but only 21 of 70 registered studies had published results. |
| Symptoms of anxiety and depression in childhood and use of MDMA: prospective, population based study 2006 | prospective longitudinal | 1580 | Opposes | Childhood anxious or depressed symptoms predicted later MDMA use (hazard ratio 2.22), suggesting depression precedes rather than results from use. |
| MDMA and MDMA-Assisted Therapy. 2025 | review | Supports | MDMA-assisted therapy in controlled settings is described as safe and efficacious for PTSD, with 67%-71% no longer meeting criteria versus 32%-48% with placebo and effects enduring at follow-up. | |
| Major depression: the relative contribution of gender, MDMA, and cannabis use 2007 | cross-sectional | 226 | No effect | Number of MDMA uses was not associated with lifetime major depressive disorder, whereas lifetime cannabis use disorder was. |
| Past-year hallucinogen use in relation to psychological distress, depression, and suicidality among US adults. 2022 | observational cohort | 241675 | Supports | Past-year ecstasy use was associated with lower likelihood of serious psychological distress, major depressive episode, and suicidal thinking, while LSD showed the opposite pattern. |
| MDMA-Assisted Therapy May Decrease PTSD Symptoms, Dissociation, Depression, and Functional Disability: A Systematic Review and Meta-Analysis 2026 | systematic review and meta-analysis | Supports | Across seven RCTs, MDMA-assisted psychotherapy may significantly improve PTSD, dissociation, depression, and functional impairment versus controls, though blinding, small samples, non-standardized therapy, and a common sponsor limit the evidence. | |
| Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials 2025 | umbrella review | Supports | MDMA showed very large effects on PTSD symptoms and psilocybin large effects on depression, with mild transient adverse events but weak long-term safety data and methodological limitations. | |
| Role of Psychedelics in Treatment-Resistant Depression. 2023 | review | Mixed | Evidence for classic psychedelics in treatment-resistant depression is limited but early results are promising, and the field may be subject to a hype bubble. | |
| [The use of psychedelics in psychiatry]. 2026 | review | Mixed | Argues that psilocybin shows consistent improvements in major depression while MDMA has the largest phase 3 dataset in PTSD but was declined FDA approval in 2024, and that certainty of evidence remains low for several indications. | |
| Placebo Effects in the Treatment of Depression-Implications for the Psychedelic Renaissance. 2026 | review | Unclear | Argues that expectancy, therapeutic setting, and trial design shape placebo effects in depression trials and are especially relevant when evaluating psychedelic-like compounds. | |
| R-MDDMA is a Safer Analogue of MDMA with Therapeutic Potential. 2026 | preclinical | Supports | An MDMA analogue (R-MDDMA) promoted neuroplasticity, fear extinction, and sustained antidepressant-like effects without abuse-related effects of MDMA. | |
| Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder 2026 | study protocol | Unclear | Protocol will test whether self-compassion during MDMA-assisted therapy predicts changes in social anxiety and depressive symptoms. | |
| MDMA-assisted PTSD and Alcohol Therapy Trial (MPATHY): study protocol for a double-blind, randomised, controlled outpatient trial of MDMA-assisted integrated exposure-based therapy for comorbid post-traumatic stress disorder and alcohol use disorder 2026 | RCT protocol | 100 | Unclear | Ongoing trial will compare MDMA-assisted exposure therapy with active-control-assisted therapy for PTSD and alcohol outcomes. |
| MDMA-assisted therapy as a treatment for major depressive disorder: proof of principle study - CORRIGENDUM. 2026 | corrigendum | Unclear | Corrigendum to a proof-of-principle study of MDMA-assisted therapy for major depressive disorder; no abstract available. | |
| Australia to prescribe MDMA and psilocybin for PTSD and depression in world first 2023 | news report | Unclear | Reports that Australia's decision to prescribe MDMA and psilocybin for PTSD and depression was described as rushed. | |
| Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics 2023 | news report | Unclear | Reports that critics called Australia's approval of MDMA and psilocybin premature, with conditions requiring authorized psychiatrists, ethics approval, and psychotherapy. | |
| MDMA and Psilocybin-Assisted Therapy in Australia: Early Real-World Prescribing, Safety Monitoring and Regulatory Developments 2026 | review | Unclear | Australia's MDMA and psilocybin prescribing pathway has grown rapidly but remains early, with authorized prescribers about 1% of the psychiatric workforce. | |
| Is it now time to prepare psychiatry for a psychedelic future? 2024 | review | Unclear | Argues that Australia's rescheduling of psilocybin and MDMA creates opportunities and challenges for psychiatry and health systems. | |
| Group psychedelic therapy: empirical estimates of cost-savings and improved access 2023 | cost analysis | Supports | Group psychedelic-assisted therapy reduced clinician costs by 50.9% for MDMA-PTSD and 34.7% for psilocybin-MDD, potentially improving access. | |
| The Use of Psychedelics in the Treatment of Medical Conditions: An Analysis of Currently Registered Psychedelics Studies in the American Drug Trial Registry. 2022 | systematic review | 105 | Unclear | Registered psychedelic trials have risen, most are early phase, and common targets include PTSD and major depressive disorder. |
| Psychedelics for Patients With Cancer: A Comprehensive Literature Review 2023 | systematic review | Supports | Across five randomized placebo-controlled trials, psychedelics significantly reduced anxiety and depression in some trials, though studies had limitations. | |
| Top Ten Tips Palliative Care Clinicians Should Know About Psychedelic-Assisted Therapy in the Context of Serious Illness. 2022 | review | Supports | Argues that psychedelic-assisted therapy can safely and effectively reduce anxiety, depression, and demoralization in seriously ill and end-of-life patients, though practical guidance is limited. | |
| Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. 2024 | cross-sectional survey | 502 | Unclear | 43% favored legalizing psychedelics for medical use but only 33% considered them safe, with attitudes predicted by experience and knowledge. |
| The Serotonin 2B (5‐ HT2B ) Receptor: A Narrative Review of Preclinical and Clinical Evidence on the Safety Considerations and Therapeutic Potential for the Treatment of Depression 2026 | narrative review | Mixed | Argues that peripheral 5-HT2B receptor agonism is linked to valvular heart disease, with limited supportive data for MDMA, while central 5-HT2B antagonism is a potential depression target. |
This synthesis reads the 15 most-cited and 10 most recent studies whose primary subject is MDMA for depression, up to 25 in all. The most-cited set anchors the established evidence, and the recent set surfaces work that is too new to have gathered citations yet.
A study qualifies only when MDMA for depression or a known alias appears in its title or keywords, so broad reviews that mention it only in passing are left out. Each study is read from its abstract, strongest evidence first, and the summary reports the direction of the results along with any conflicts and gaps.
The full method, including what a person does and does not review, is on the methods page.
54 articles · 19 from the last two years · 247,994 participants across 22 studies reporting sample size
53 studies whose primary subject is MDMA for depression since 2004
| Year | Studies |
|---|---|
| 2004 | 1 |
| 2005 | 0 |
| 2006 | 3 |
| 2007 | 2 |
| 2008 | 0 |
| 2009 | 0 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 0 |
| 2013 | 0 |
| 2014 | 2 |
| 2015 | 0 |
| 2016 | 0 |
| 2017 | 3 |
| 2018 | 3 |
| 2019 | 0 |
| 2020 | 0 |
| 2021 | 2 |
| 2022 | 5 |
| 2023 | 5 |
| 2024 | 5 |
| 2025 | 10 |
| 2026 | 9 |
Orvosi hetilap September 13, 2026 Szabolcs Kéri
Over the past five years, the literature on the psychiatric use of psychedelic and related treatments has expanded substantially. Several randomized controlled trials and pooled analyses have been conducted in mood disorders, treatment-resistant depression, and post-traumatic stress disorder. Trial methodology, however, remains a fundamental source of uncertainty, and despite the popularity of...
Harvard Review of Psychiatry September 8, 2026 Warwick M. Green, Sanket B Raut, F. E. James et al.
There is a need for new effective treatment options for posttraumatic stress disorder (PTSD), as many people with PTSD do not fully recover despite current treatments. 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy (MDMA-AT) is emerging as a new treatment option. We assessed the current body of MDMA-AT evidence for effectiveness in treating PTSD, associated impairments, and...
July 12, 2026 Octavian Brinzei
Australia became the first country to establish a national regulatory pathway permitting authorised psychiatrists to prescribe 3,4-methylenedioxymethamphetamine (MDMA) for post-traumatic stress disorder (PTSD) and psilocybin for treatment-resistant depression (TRD) through the Therapeutic Goods Administration (TGA) Authorised Prescriber Scheme. Two and a half years after implementation,...
BMJ Open July 1, 2026 Kirsten Morley, Shalini Arunogiri, Katherine L. Mills et al.
INTRODUCTION: The treatment of comorbid post-traumatic stress disorder (PTSD) and alcohol use disorder (AUD) is significantly more challenging than the treatment of either disorder alone. While gold standard evidence-based treatments exist for this comorbidity, clinically significant improvements are only observed in approximately half of clinical trial participants. The use of adjunctive...
Clinical Pharmacology & Therapeutics May 28, 2026 Gia Han Le, Sabrina Wong, Danica E. Johnson et al.
Major depressive disorder (MDD) and treatment-resistant depression (TRD) remain leading causes of disability, providing the impetus for receptor-level treatment strategies beyond monoamine reuptake. The serotonin 5-HT2B receptor (5-HT2BR) is uniquely positioned at the interface of central-antidepressant mechanisms and peripheral cardiac risks. Herein, we reviewed preclinical, translational and...
ACS Chemical Neuroscience May 6, 2026 Maxemiliano V. Vargas, Cassandra J. Hatzipantelis, Lee E. Dunlap et al.
Recent clinical evidence suggests that racemic 3,4-methylenedioxymethamphetamine (MDMA) might be useful for treating a range of neuropsychiatric diseases including post-traumatic stress disorder (PTSD) and depression. However, concerns about its abuse potential stemming from its monoamine releasing properties have hampered its clinical development. Thus, safer analogues of racemic MDMA with...
The British Journal of Psychiatry February 10, 2026 Tor-Morten Kvam, Ivar W Goksøyr, Justyna Rog et al.
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.
Neurologic Clinics February 1, 2026 Mina Ansari, Sophie I Elliott, Sophie E Holmes et al. 1 citation
The development of novel, rapid-acting treatments and the resurgence of interest in the therapeutic potential of psychedelic-like compounds has stimulated excitement and enthusiasm within the pharmaceutical industry, and provided new hope for millions of individuals suffering with mental illness such as major depressive disorder and post-traumatic stress disorder. This review summarizes the...
Open Science Framework 2026 Christina Chwyl, M. Kati Lear, Sunjeev K. Kamboj et al. preprint
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorder (SAD). One proposed mechanism of MDMA-assisted therapy (MDMA-AT) for SAD is the cultivation of self-compassion. Across five aims, we will characterize self-compassion experiences during MDMA-AT and evaluate its role as a potential mechanism of...
Journal of Clinical Medicine December 29, 2025 Monika Dominiak, Adam Gędek, Szymon Modrzejewski et al. 2 citations
Background: Psychedelic-assisted therapy is gaining renewed attention as a potential treatment for various mental disorders. Despite increasing numbers of randomized controlled trials (RCTs) and meta-analyses, a comprehensive synthesis of the evidence across different substances and indications is lacking. This umbrella review aims to evaluate the effectiveness and safety of...
Completed 759 participants Indiana University